Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease
2020-000433-40Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of amiloride in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Erasmus MC. Primary endpoint: Central pulse wave velocity with or without high-salt diet. Started Aug 2021; status: active.
02
Drugs
amiloride
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2020-000433-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000433-40.